Phase II trial of carboplatin in patients with metastatic malignant melanoma

A. Chang, M. Hunt, D. R. Parkinson, H. Hochster, T. J. Smith

Research output: Contribution to journalArticlepeer-review

18 Scopus citations

Abstract

Thirty patients with pathologically proven, measurable metastatic melanoma without prior chemotherapy were treated with carboplatin 400 mg/m2 by intravenous infusion for 30 minutes every 4 weeks. Twenty-seven patients were evaluable for response and toxicity. Two complete responses and one partial response (3 of 27 = 11%, 90% confidence intervals: 3-26%) were documented. The median survival was 4.7 months. The most common toxicity was myelosuppression. One drug-related death was observed due to renal failure. Prior radiotherapy and liver metastasis were the poor prognostic indicators identified in our study. Carboplatin in the dose and schedule reported in our trial has only modest antitumor activity in patients with advanced malignant melanoma.

Original languageEnglish (US)
Pages (from-to)152-155
Number of pages4
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume16
Issue number2
DOIs
StatePublished - 1993

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase II trial of carboplatin in patients with metastatic malignant melanoma'. Together they form a unique fingerprint.

Cite this